Published in Vaccine Weekly, November 2nd, 1998
N. French and colleagues at the University of Minnesota assessed the feasibility of establishing a pneumococcal vaccine trial among HIV-1-infected adults in a community clinic in Entebbe, Uganda, and to characterize their responses to 23-valent pneumococcal polysaccharide vaccine ("Pneumococcal Vaccination in HIV-1-Infected Adults in Uganda: Humoral Response and Two Vaccine Failures," AIDS, September 10, 1998;12(13):1683-1689).
An open-label pilot trial was used to evaluate recruitment and compliance of HIV-1-infected adults to vaccination...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly